ATE396982T1 - Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors - Google Patents

Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors

Info

Publication number
ATE396982T1
ATE396982T1 AT04810027T AT04810027T ATE396982T1 AT E396982 T1 ATE396982 T1 AT E396982T1 AT 04810027 T AT04810027 T AT 04810027T AT 04810027 T AT04810027 T AT 04810027T AT E396982 T1 ATE396982 T1 AT E396982T1
Authority
AT
Austria
Prior art keywords
vitamin
compounds
receptor
phenylfuran
modulators
Prior art date
Application number
AT04810027T
Other languages
English (en)
Inventor
Robert Gajewski
Charles Jones
Jianliang Lu
Tianwei Ma
Sunil Nagpal
Ying Yee
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE396982T1 publication Critical patent/ATE396982T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Pyrane Compounds (AREA)
AT04810027T 2003-11-20 2004-11-16 Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors ATE396982T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52401503P 2003-11-20 2003-11-20

Publications (1)

Publication Number Publication Date
ATE396982T1 true ATE396982T1 (de) 2008-06-15

Family

ID=34632855

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04810027T ATE396982T1 (de) 2003-11-20 2004-11-16 Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors

Country Status (8)

Country Link
US (1) US7468449B2 (de)
EP (1) EP1692123B1 (de)
JP (1) JP4750713B2 (de)
AT (1) ATE396982T1 (de)
CA (1) CA2546729A1 (de)
DE (1) DE602004014188D1 (de)
ES (1) ES2307069T3 (de)
WO (1) WO2005051936A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101978A1 (en) * 2002-05-29 2003-12-11 Eli Lilly And Company Phenyl-thiophene type vitamin d receptor modulators
DE60326082D1 (de) 2002-11-22 2009-03-19 Lilly Co Eli Modulatoren von vitamin d rezeptoren
CA2544501A1 (en) 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
EP1687289A1 (de) * 2003-11-20 2006-08-09 Eli Lilly And Company Modulatoren des vitamin-d-rezeptors
WO2005051940A2 (en) * 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
EP1692123B1 (de) 2003-11-20 2008-05-28 Eli Lilly And Company Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors
US7750184B2 (en) 2003-11-20 2010-07-06 Eli Lilly And Company Vitamin D receptor modulators
MX2007007439A (es) * 2004-12-21 2007-09-06 Lilly Co Eli Moduladores del receptor de la vitamina d.
KR100931777B1 (ko) * 2004-12-21 2009-12-14 일라이 릴리 앤드 캄파니 비타민 d 수용체 조절제
US9370527B2 (en) 2012-12-28 2016-06-21 The Regents Of The University Of Michigan Amelioration of intestinal fibrosis and treatment of Crohn's disease
CN103193695B (zh) * 2013-04-22 2015-08-05 中国药科大学 3-苯基-3-吡咯基戊烷类衍生物及其医药用途
CN108602791B (zh) * 2015-11-06 2023-07-14 明尼苏达大学评议会 芳族表面活性剂
EP3371159B1 (de) 2015-11-06 2021-10-27 Regents of the University of Minnesota Verfahren zur herstellung aromatenhaltiger verbindungen
CN106908559B (zh) * 2015-12-23 2020-08-11 重庆华邦胜凯制药有限公司 卡泊三醇中间体l及相关杂质的分离与测定方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282246A (en) * 1980-03-07 1981-08-04 Pfizer Inc. Antidiabetic furancarboxylic and thiphenecarboxylic acids
US6218430B1 (en) * 1998-08-24 2001-04-17 Ligand Pharmaceuticals Incorporated Vitamin D3 mimics
WO2003101978A1 (en) 2002-05-29 2003-12-11 Eli Lilly And Company Phenyl-thiophene type vitamin d receptor modulators
DE10229456A1 (de) * 2002-07-01 2004-02-05 Wank, Rudolf, Prof. Dr.med. Verwendung von Dopamin-Rezeptor-Agonisten zur Behandlung von Hautgeschwülsten und Warzen
EP1587906A2 (de) 2003-01-10 2005-10-26 Eli Lilly And Company Vesikansbehandlung mit vitamin-d-rezeptormodulatoren des phenyl-phenyl-typs
WO2004063348A2 (en) 2003-01-10 2004-07-29 Eli Lilly And Company Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators
EP1687289A1 (de) 2003-11-20 2006-08-09 Eli Lilly And Company Modulatoren des vitamin-d-rezeptors
WO2005051940A2 (en) * 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
EP1692123B1 (de) 2003-11-20 2008-05-28 Eli Lilly And Company Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors
US7750184B2 (en) 2003-11-20 2010-07-06 Eli Lilly And Company Vitamin D receptor modulators
CA2544501A1 (en) 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators

Also Published As

Publication number Publication date
WO2005051936A1 (en) 2005-06-09
US7468449B2 (en) 2008-12-23
EP1692123B1 (de) 2008-05-28
DE602004014188D1 (de) 2008-07-10
EP1692123A1 (de) 2006-08-23
CA2546729A1 (en) 2005-06-09
JP4750713B2 (ja) 2011-08-17
JP2007512326A (ja) 2007-05-17
US20070105951A1 (en) 2007-05-10
ES2307069T3 (es) 2008-11-16

Similar Documents

Publication Publication Date Title
CY1108988T1 (el) Διαμορφωτες υποδοχεα βιταμινης d
CY1109341T1 (el) Διαμορφωτες υποδοχεα βιταμινης d τυπου φαινυλο-θειοφαινιου
DE602004014188D1 (de) Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors
ATE370941T1 (de) Modulatoren des vitamin-d-rezeptors
MY137053A (en) Pyrimidine derivatives and their use as cb2 modulators
ATE534293T1 (de) Diarylaminhaltige verbindungen und zusammensetzungen und deren verwendung als modulatoren von c-kit-rezeptoren
ATE345329T1 (de) Pyridinderivate als modulatoren des cb2-rezeptors
MX2010005028A (es) Moduladores de gamma secretasa.
CY1110555T1 (el) 4-((φαινοξυαλκυλ)θειο)-φαινοξυοξεικα οξεα και αναλογα
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
WO2005051893A3 (en) Vitamin d receptor modulators
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
ATE543796T1 (de) 24-sulfoximine vitamin d3 derivate
ATE537834T1 (de) 2-methylen-19-nor-vitamin d2-verbindungen
ATE340785T1 (de) 2-phenylamino-4-trifluoromethyl-5-(benzyl- oder pyridin-4-ylmethyl)carbamoylpyrimidin-derivate als selektive cb2 cannabinoid-rezeptor modulatoren
AU2003252025A8 (en) Compounds, compositions, and methods
CY1110326T1 (el) Υποκατασταθεισες τετραλινες και ινδανια και η χρηση τους
ATE455749T1 (de) Verbindungen mit verbrückten ringen als pharmazeutische mittel
ATE509269T1 (de) Verfahren und verbindungen zur modulierung von apoptosis
GB0324656D0 (en) A protein involved in ovarian cancer
DE602005027322D1 (de) Verwendung von antikörpern gegen tweak zur behandlung von schlaganfall
EP1474434A4 (de) Der eaat2-promotor und dessen verwendung
AU2002251873A1 (en) Methods and compositions for modulating gluconeogenesis using pgc-1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties